[(2R,5R)-4,4-difluoro-3-hydroxy-5-[2-oxo-4-[(2,2,2-trifluoroacetyl)amino]pyrimidin-1-yl]oxolan-2-yl]methyl 5-[[7-[3-[2-(2-methoxyethoxy)ethoxy]propanoylamino]-2-oxoheptan-3-yl]amino]-5-oxopentanoate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: [(2R,5R)-4,4-difluoro-3-hydroxy-5-[2-oxo-4-[(2,2,2-trifluoroacetyl)amino]pyrimidin-1-yl]oxolan-2-yl]methyl 5-[[7-[3-[2-(2-methoxyethoxy)ethoxy]propanoylamino]-2-oxoheptan-3-yl]amino]-5-oxopentanoate
• 化学式: C₃₁H₄₄F₅N₅O₁₂
• 分子量: 773.7
• InChiKey: YEORQFZTLTUCPN-PWGSTHNOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  53
• 可旋转键数：
  25
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  221
• 氢给体数：
  4
• 氢受体数：
  17

文献信息

• MACROMOLECULES
  申请人：Owen David

  公开号：US20140171375A1

  公开（公告）日：2014-06-19

  The present invention relates to a macromolecule comprising a dendrimer having surface amino groups to which at least two different terminal groups are attached including a pharmaceutically active agent and a pharmacokinetic modifying agent, the pharmaceutically active agent comprising a hydroxyl group and being attached to the surface amino group of the dendrimer through a diacid linker. Pharmaceutical compositions comprising the macromolecules and methods of treatment using the macromolecules are also described.
• US9744246B2
  申请人：——

  公开号：US9744246B2

  公开（公告）日：2017-08-29